tetano
Editor, Senior Moderator
Am J Med Sci
. 2025 Nov 21:S0002-9629(25)01274-1.
doi: 10.1016/j.amjms.2025.11.007. Online ahead of print. Real World Evaluation of Evusheld in Prevention of COVID-19 in Immunocompromised Patients: An Observational Cohort Study
Sarah Channey[SUP] 1 [/SUP], Pramodini Kale-Pradhan[SUP] 2 [/SUP], Mamta Sharma[SUP] 3 [/SUP], Daniel Lebovic[SUP] 4 [/SUP], Christopher Giuliano[SUP] 5 [/SUP], Leonard Johnson[SUP] 6 [/SUP], Ashish Bhargava[SUP] 7 [/SUP]
Affiliations
Background: Evusheld®, a combination of monoclonal antibodies Tixagevimab and Cilgavimab, was developed for pre-exposure prophylaxis (PrEP) of coronavirus disease 2019 (COVID-19) in immunocompromised patients. However, real-world long-term data on its effectiveness against SARS-CoV-2 Omicron variants remain limited.
Methods: A retrospective cohort was conducted on patients ≥18 years old who received the Evusheld from December 1, 2021, to January 31, 2023, at six Ascension hospitals in Southeast Michigan. Patients included were those with active solid tumor and hematologic malignancies or undergoing immunosuppressive treatment, including CAR-T therapy, biologic agents, or high-dose corticosteroids (≥20 mg prednisone or equivalent per day for ≥2 weeks). Data collected included patient demographics, development of COVID-19 post-Evusheld, ICU length of stay (LOS), hospital LOS, ventilation requirement and duration, and mortality within six months post-therapy.
Results: Among 663 patients screened, 316 were included after excluding duplicates and patients that did not receive the ordered Evusheld regimen. Among them, 204 patients received two doses of Evusheld and 112 received only one dose. In the two-dose group, 18 (8.8%) tested positive for COVID-19 within 180 days post-Evusheld, while 11 (9.8%) in the one-dose group tested positive. Notably, none of the COVID-positive patients in either group required hospitalization, mechanical ventilation, or succumbed to the disease.
Conclusion: Within six months of Evusheld administration, immunocompromised patients showed no episodes of rehospitalization, mechanical ventilation, or death, and experienced low rates of severe COVID-19.
Keywords: Breakthrough infection; COVID-19; Evusheld; Hematologic malignancies; Immunosuppressed patients; Monoclonal antibodies; Pre-exposure prophylaxis; Solid tumors; Tixagevimab-Cilgavimab.
. 2025 Nov 21:S0002-9629(25)01274-1.
doi: 10.1016/j.amjms.2025.11.007. Online ahead of print. Real World Evaluation of Evusheld in Prevention of COVID-19 in Immunocompromised Patients: An Observational Cohort Study
Sarah Channey[SUP] 1 [/SUP], Pramodini Kale-Pradhan[SUP] 2 [/SUP], Mamta Sharma[SUP] 3 [/SUP], Daniel Lebovic[SUP] 4 [/SUP], Christopher Giuliano[SUP] 5 [/SUP], Leonard Johnson[SUP] 6 [/SUP], Ashish Bhargava[SUP] 7 [/SUP]
Affiliations
- PMID: 41276115
- DOI: 10.1016/j.amjms.2025.11.007
Background: Evusheld®, a combination of monoclonal antibodies Tixagevimab and Cilgavimab, was developed for pre-exposure prophylaxis (PrEP) of coronavirus disease 2019 (COVID-19) in immunocompromised patients. However, real-world long-term data on its effectiveness against SARS-CoV-2 Omicron variants remain limited.
Methods: A retrospective cohort was conducted on patients ≥18 years old who received the Evusheld from December 1, 2021, to January 31, 2023, at six Ascension hospitals in Southeast Michigan. Patients included were those with active solid tumor and hematologic malignancies or undergoing immunosuppressive treatment, including CAR-T therapy, biologic agents, or high-dose corticosteroids (≥20 mg prednisone or equivalent per day for ≥2 weeks). Data collected included patient demographics, development of COVID-19 post-Evusheld, ICU length of stay (LOS), hospital LOS, ventilation requirement and duration, and mortality within six months post-therapy.
Results: Among 663 patients screened, 316 were included after excluding duplicates and patients that did not receive the ordered Evusheld regimen. Among them, 204 patients received two doses of Evusheld and 112 received only one dose. In the two-dose group, 18 (8.8%) tested positive for COVID-19 within 180 days post-Evusheld, while 11 (9.8%) in the one-dose group tested positive. Notably, none of the COVID-positive patients in either group required hospitalization, mechanical ventilation, or succumbed to the disease.
Conclusion: Within six months of Evusheld administration, immunocompromised patients showed no episodes of rehospitalization, mechanical ventilation, or death, and experienced low rates of severe COVID-19.
Keywords: Breakthrough infection; COVID-19; Evusheld; Hematologic malignancies; Immunosuppressed patients; Monoclonal antibodies; Pre-exposure prophylaxis; Solid tumors; Tixagevimab-Cilgavimab.